An international, multicentre, double-blind, randomized study
(DISSCO): effect of diacerein vs celecoxib on symptoms in knee
osteoarthritis

J 2020

An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis

PELLETIER, J. P.; J. P. RAYNAULD; M. DORAIS; L. BESSETTE; Eva DOKOUPILOVÁ et al.

Základní údaje

Originální název

An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis

Autoři

PELLETIER, J. P.; J. P. RAYNAULD; M. DORAIS; L. BESSETTE; Eva DOKOUPILOVÁ; F. MORIN; K. PAVELKA; P. PAIEMENT a J. MARTEL-PELLETIER

Vydání

RHEUMATOLOGY, OXFORD, OXFORD UNIV PRESS, 2020, 1462-0324

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.580

Kód RIV

RIV/00216224:14160/20:00118261

Organizační jednotka

Farmaceutická fakulta

DOI

https://doi.org/10.1093/rheumatology/keaa072

UT WoS

000606837500054

EID Scopus

2-s2.0-85098471580

Klíčová slova anglicky

diacerein; celecoxib; osteoarthritis; non-inferiority trial; SYSADOA

Štítky

rivok, ÚFT

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 2. 2021 08:18, Mgr. Hana Hurtová

Anotace

V originále

Objective. The objective of this study was to investigate whether diacerein has comparable efficacy with celecoxib in pain reduction for treatment in symptomatic knee OA patients. Methods. This randomized double-blind multicentre non-inferiority trial evaluated diacerein vs celecoxib treatment in patients with Kellgren-Lawrence grade 2-3 and pain scoring >= 4 (10-cm VAS). Patients were randomized to 6 months of treatment with diacerein 50 mg (n = 1 87) once daily for 1 month and twice daily thereafter, or celecoxib 200mg (n =193) once daily. The primary outcome was the change in WOMAC pain score (0-50 cm) at 6 months, and the secondary outcomes were WOMAC sub-scores, VAS pain score, and the OMERACT-OARSI responder rate. Results. In the per protocol population, the adjusted mean change from baseline in the WOMAC pain score was -11.1 (0.9) with diacerein (n = 1 40) and -11.8(0.9) with celecoxib (n = 1 48). The intergroup difference was 0.7 (95% CI: -1.8, 3.2; P = 0.597), meeting the non-inferiority margin. Supportive analysis of the intention-to-treat population gave similar results. Other outcomes showed no significant difference between treatment groups. The incidence of treatment-related adverse events was low and balanced between groups, but a greater incidence of diarrhoea occurred with diacerein (10.2% vs 3.7%). Diarrhoea was considered mild-to-moderate in all but one case with complete resolution. Conclusions. Diacerein was non-inferior to celecoxib in reducing knee OA pain and improving physical function. Diacerein also demonstrated a good safety profile.

Citovat

PELLETIER, J. P.; J. P. RAYNAULD; M. DORAIS; L. BESSETTE; Eva DOKOUPILOVÁ; F. MORIN; K. PAVELKA; P. PAIEMENT a J. MARTEL-PELLETIER. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. RHEUMATOLOGY. OXFORD: OXFORD UNIV PRESS, 2020, roč. 59, č. 12, s. 3858-3868. ISSN 1462-0324. Dostupné z: https://doi.org/10.1093/rheumatology/keaa072.

@article{1746196,
   author = {Pelletier, J. P. and Raynauld, J. P. and Dorais, M. and Bessette, L. and Dokoupilová, Eva and Morin, F. and Pavelka, K. and Paiement, P. and MartelandPelletier, J.},
   article_location = {OXFORD},
   article_number = {12},
   doi = {https://doi.org/10.1093/rheumatology/keaa072},
   keywords = {diacerein; celecoxib; osteoarthritis; non-inferiority trial; SYSADOA},
   language = {eng},
   issn = {1462-0324},
   journal = {RHEUMATOLOGY},
   title = {An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis},
   url = {https://pubmed.ncbi.nlm.nih.gov/32521015/},
   volume = {59},
   year = {2020}
}

TY  - JOUR
ID  - 1746196
AU  - Pelletier, J. P. - Raynauld, J. P. - Dorais, M. - Bessette, L. - Dokoupilová, Eva - Morin, F. - Pavelka, K. - Paiement, P. - Martel-Pelletier, J.
PY  - 2020
TI  - An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis
JF  - RHEUMATOLOGY
VL  - 59
IS  - 12
SP  - 3858-3868
EP  - 3858-3868
PB  - OXFORD UNIV PRESS
SN  - 14620324
KW  - diacerein
KW  - celecoxib
KW  - osteoarthritis
KW  - non-inferiority trial
KW  - SYSADOA
UR  - https://pubmed.ncbi.nlm.nih.gov/32521015/
N2  - Objective. The objective of this study was to investigate whether diacerein has comparable efficacy with celecoxib in pain reduction for treatment in symptomatic knee OA patients. Methods. This randomized double-blind multicentre non-inferiority trial evaluated diacerein vs celecoxib treatment in patients with Kellgren-Lawrence grade 2-3 and pain scoring >= 4 (10-cm VAS). Patients were randomized to 6 months of treatment with diacerein 50 mg (n = 1 87) once daily for 1 month and twice daily thereafter, or celecoxib 200mg (n =193) once daily. The primary outcome was the change in WOMAC pain score (0-50 cm) at 6 months, and the secondary outcomes were WOMAC sub-scores, VAS pain score, and the OMERACT-OARSI responder rate. Results. In the per protocol population, the adjusted mean change from baseline in the WOMAC pain score was -11.1 (0.9) with diacerein (n = 1 40) and -11.8(0.9) with celecoxib (n = 1 48). The intergroup difference was 0.7 (95% CI: -1.8, 3.2; P = 0.597), meeting the non-inferiority margin. Supportive analysis of the intention-to-treat population gave similar results. Other outcomes showed no significant difference between treatment groups. The incidence of treatment-related adverse events was low and balanced between groups, but a greater incidence of diarrhoea occurred with diacerein (10.2% vs 3.7%). Diarrhoea was considered mild-to-moderate in all but one case with complete resolution. Conclusions. Diacerein was non-inferior to celecoxib in reducing knee OA pain and improving physical function. Diacerein also demonstrated a good safety profile.
ER  -

PELLETIER, J. P.; J. P. RAYNAULD; M. DORAIS; L. BESSETTE; Eva DOKOUPILOVÁ; F. MORIN; K. PAVELKA; P. PAIEMENT a J. MARTEL-PELLETIER. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. \textit{RHEUMATOLOGY}. OXFORD: OXFORD UNIV PRESS, 2020, roč.~59, č.~12, s.~3858-3868. ISSN~1462-0324. Dostupné z: https://doi.org/10.1093/rheumatology/keaa072.

Přehled o publikaci